| Entry |
|
|---|
| Name |
Inotuzumab ozogamicin (USAN/INN);
Inotuzumab ozogamicin (genetical recombination) (JAN);
Besponsa (TN)
|
|---|
| Product |
|
|---|
| Formula |
C6518H10002N1738O2036S42
|
|---|
| Exact mass |
146542.0817
|
|---|
| Mol weight |
146632.3115
|
|---|
| Remark |
| Therapeutic category: | 4239 |
|
|---|
| Efficacy |
Antineoplastic, DNA synthesis inhibitor, Anti-CD22 antibody |
|---|
| Disease |
B-cell precursor acute lymphoblastic leukemia [DS: H00001] |
|---|
| Comment |
Antibody-drug conjugate
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04662 | B cell receptor signaling pathway |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XC Monoclonal antibodies
L01XC26 Inotuzumab ozogamicin
D08933 Inotuzumab ozogamicin (USAN/INN) <JP/US>
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
423 Antibiotics
4239 Others
D08933 Inotuzumab ozogamicin (USAN/INN); Inotuzumab ozogamicin (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
Cell surface molecules and ligands
Cell adhesion molecules: Ig superfamiy
SIGLEC family
CD22
D08933 Inotuzumab ozogamicin (USAN/INN) <JP/US>
Antineoplastics [br08340.html]
D08933
New drug approvals in the USA [br08319.html]
New Molecular Entity and New Therapeutic Biological Product Approvals
D08933
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D08933
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D08933
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D08933
Pharmacogenomic biomarkers [br08341.html]
Companion diagnostics
D08933
 |
|---|
| Other DBs |
|
|---|
| LinkDB |
 |
|---|
